A survey of 86 German patient groups suggests pharma’s reputation is improving in the country that has been wary of pharma in the past, with Amgen and Janssen leading the way.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh